drugset
drugset / Trial / NCT01298752

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01298752 ↗

Phase 3 Terminated 177 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Timeline

Start
2011-02
Primary completion
2011-09
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mapracorat Small molecule 3 % Other

Indications

cataract